Key Drivers
- Margin resilience
- Liquidity pressure
- Leverage creep
AIAI Summary
CHE is now best viewed as a more concentrated, VITAS-led earnings story rather than a broad, steady compounder: hospice margin/census gains are the main upside driver, but with valuation already rich and Roto-Rooter still weak, the stock needs sustained VITAS execution to justify further re-rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin resilience
- •Liquidity pressure
- •Leverage creep
CHE remains fundamentally strong with solid margins, cash flow, and exceptional interest coverage, but tighter liquidity, rising leverage, and a richer valuation temper the outlook.
Price Behavior
Key Price Behavior Insights:
- •Uptrend intact
- •Resistance capped
- •Support cluster
CHE remains constructive over the last month, but after peaking at $552.72 it has slipped back into the $532–$535 support zone, signaling consolidation with upside still capped near $549–$553.
Price peaked at $552.72, then eased back to $532.88, suggesting consolidation after the rally
Sentiment & News
Key News Insights:
- •VITAS Growth
- •Dividend Increase
- •Spin-off Talk
Chemed posted strong Q2 results led by VITAS's double-digit growth, raised its dividend, and drew renewed bullish attention to a potential spin-off and valuation rerating.
The latest news is likely supportive for CHE shares, as strong earnings and higher capital returns outweigh mixed margin pressure in Roto-Rooter
Similar Companies in Healthcare
Other companies in the same sector with AI ratings